



Novo Nordisk in the United States

At Novo Nordisk, we believe in change. We seek opportunities to contribute to healthier communities and better lives for all people. And we drive change by listening, learning and improving.

For more than 90 years we have been driving change to defeat diabetes, inspired by the courage of the people we support. Our heritage in diabetes has given us the experience and capability to help defeat other serious chronic conditions: hemophilia, growth disorders and obesity.

Every change in the right direction counts, from innovations in medicines and embarking on new partnerships to the everyday efforts and choices that people living with a chronic condition make as they strive to live the life they want.

We work for a future where lives are not limited. To achieve this, we take the lead and continuously challenge the status quo by looking at change from new perspectives.



SEATTLE, WA



INDIANAPOLIS, IN




WEST LEBANON, NH



CLAYTON, NC



PLAINSBORO, NJ



FAST FACTS

 ESTABLISHED IN **1923**, COPENHAGEN, DENMARK

 US HEADQUARTERS IN **PLAINSBORO, NJ**, WITH LOCATIONS IN **5 STATES**

 NEARLY **5,000** EMPLOYEES

 APPROXIMATELY **500** PEOPLE WORKING IN **R&D** IN THE U.S.

 WORKING WITHIN **DIABETES, HEMOPHILIA, GROWTH DISORDERS AND OBESITY**

 **\$8.5 BILLION** TOTAL U.S. SALES IN 2016

 APPROXIMATELY **210,000** SHAREHOLDERS

 **14 MEDICINES** MARKETED ACROSS THERAPEUTIC AREAS

 **PATIENT ASSISTANCE PROGRAM** MAINTAINED FOR ELIGIBLE PATIENTS WHO MAY BE HAVING A CHALLENGE AFFORDING THEIR MEDICINES

Actions that Drive Change

Making life-saving medicine is a significant responsibility—millions of people depend on us. However, to defeat serious chronic conditions, we need to do more. Below are some of our activities and programs in the US.

changing diabetes®

Since Novo Nordisk was founded 90 years ago, we have been changing diabetes. Our key contribution is to discover and develop better medicines. However, to defeat this serious disease, we need to do more to address the unmet needs of people with diabetes.

changing hemophilia™

For more than three decades, Novo Nordisk has been committed to changing hemophilia. In addition to discovering and developing effective medicines, we work with our community partners to improve the lives of people with hemophilia by creating better access to diagnosis and multidisciplinary care. We envision a future where everyone with hemophilia is freed from the burden of the disease.

Cornerstones4Care®

Cornerstones4Care® delivers personalized support based on a person's individual needs so that they feel more empowered to manage their diabetes. Healthy eating, being active, diabetes medicine and tracking—patients manage what's most important to them, all in one place. It includes topics that can be put into practice, interactive tracking tools and other helpful resources like live CDE phone calls with the Diabetes Health Coach.

World Diabetes Day, World Hemophilia Day and National Obesity Care Week

Every year on World Diabetes Day on November 14, and World Hemophilia Day on April 17, Novo Nordisk, together with international and local organizations, unites communities to raise awareness of these chronic conditions. We also support the vision of National Obesity Care Week (last week of October/first week of November), an annual initiative to inspire a coalition effort to achieve a comprehensive, compassionate and patient-centric approach to obesity care.

Grants and Corporate Giving


We are committed to making a difference by supporting scientific and humanitarian causes that positively impact lives. For example, as part of our commitment to the Triple Bottom Line, Novo Nordisk launched the Community Health Collaborative™, a grant program designed to support community-based initiatives that address urban health and wellness, particularly near our US offices in Trenton, NJ, and the surrounding communities.

Diabetes Advocacy Alliance™ (DAA)

Novo Nordisk is a founding member of the DAA, a coalition representing patient, professional and trade associations, other nonprofit organizations and corporations, all united in the desire to change the way diabetes is viewed and treated in America. The vision of the DAA is to influence change in the US healthcare system to improve diabetes prevention, detection and care, and to speed the development of pathways to cures for diabetes.

THE TRIPLE BOTTOM LINE

To ensure that we can be in business for the next generations, we must always act responsibly, considering the impact of our business on people, communities and the environment when we make decisions. We call this approach the Triple Bottom Line.



About Novo Nordisk

Novo Nordisk is a global health care company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: hemophilia, growth disorders and obesity. With U.S. headquarters in Plainsboro, N.J., Novo Nordisk Inc. has nearly 5,000 employees in the United States. For more information, visit novonordisk.us or follow us on Twitter: [@novonordiskus](https://twitter.com/novonordiskus).

US Headquarters Location

800 Scudders Mill Rd
Plainsboro Township, NJ 08536